Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Increased to $831.00 by Analysts at HC Wainwright

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target upped by HC Wainwright from $787.00 to $831.00 in a report issued on Wednesday, The Fly reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. Benchmark raised their target price on shares of Regeneron Pharmaceuticals from $636.00 to $727.00 and gave the company a buy rating in a research report on Monday, August 23rd. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $625.00 to $669.00 and gave the company an outperform rating in a research report on Friday, August 6th. UBS Group started coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, September 9th. They issued a buy rating and a $763.00 price target on the stock. SVB Leerink raised their price target on shares of Regeneron Pharmaceuticals from $641.00 to $725.00 and gave the company an outperform rating in a report on Friday, August 6th. Finally, Barclays raised their price target on shares of Regeneron Pharmaceuticals from $675.00 to $705.00 and gave the company an overweight rating in a report on Friday, August 6th. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of Buy and an average price target of $691.65.

REGN stock opened at $651.88 on Wednesday. The company has a market capitalization of $69.72 billion, a PE ratio of 11.71, a P/E/G ratio of 0.77 and a beta of 0.16. Regeneron Pharmaceuticals has a 12 month low of $441.00 and a 12 month high of $686.62. The firm’s 50-day moving average is $625.48 and its 200 day moving average is $545.68. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.57 and a quick ratio of 3.04.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 5th. The biopharmaceutical company reported $25.80 EPS for the quarter, beating analysts’ consensus estimates of $8.81 by $16.99. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $3.90 billion. Regeneron Pharmaceuticals had a net margin of 50.11% and a return on equity of 50.43%. Sell-side analysts forecast that Regeneron Pharmaceuticals will post 51.91 EPS for the current fiscal year.

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Thursday, July 1st. The shares were sold at an average price of $564.50, for a total value of $56,450.00. Following the completion of the sale, the director now owns 23,589 shares of the company’s stock, valued at approximately $13,315,990.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director George L. Sing sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 30th. The stock was sold at an average price of $672.50, for a total transaction of $672,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 389,040 shares of company stock valued at $240,594,454. Insiders own 11.84% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in REGN. Dimensional Fund Advisors LP increased its stake in Regeneron Pharmaceuticals by 5.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 236,843 shares of the biopharmaceutical company’s stock worth $114,415,000 after purchasing an additional 11,978 shares during the period. Commonwealth Equity Services LLC increased its stake in Regeneron Pharmaceuticals by 20.2% during the first quarter. Commonwealth Equity Services LLC now owns 14,206 shares of the biopharmaceutical company’s stock worth $6,721,000 after purchasing an additional 2,390 shares during the period. Envestnet Asset Management Inc. increased its stake in Regeneron Pharmaceuticals by 5.4% during the first quarter. Envestnet Asset Management Inc. now owns 64,762 shares of the biopharmaceutical company’s stock worth $30,641,000 after purchasing an additional 3,335 shares during the period. Los Angeles Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 625.8% during the first quarter. Los Angeles Capital Management LLC now owns 25,644 shares of the biopharmaceutical company’s stock worth $12,133,000 after buying an additional 22,111 shares during the period. Finally, Interchange Capital Partners LLC increased its stake in shares of Regeneron Pharmaceuticals by 347.1% during the first quarter. Interchange Capital Partners LLC now owns 380 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 295 shares during the period. 82.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Featured Story: How do buyers and sellers choose a strike price?

The Fly logo

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.